Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AZD1656 + pioglitazone
- Development stage
- Phase 1
- Lead developer
- Conduit Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**AZD1656 + pioglitazone** is a combination therapy under investigation for the treatment of type 2 diabetes mellitus. AZD1656 is a glucokinase activator developed to enhance glucose-dependent insulin release by increasing the activity of glucokinase, a key enzyme in the regulation of carbohydrate metabolism. Pioglitazone is a thiazolidinedione that acts as an agonist of the peroxisome proliferator-activated receptor gamma (PPARγ), thereby improving insulin sensitivity. The combination is designed to leverage both improved insulin release (from AZD1656) and increased insulin sensitivity (from pioglitazone) to achieve better glycemic control in diabetes patients. A phase 1 clinical trial (cross-over design) evaluated the pharmacokinetics and safety of the combination in type 2 diabetic patients treated with metformin[1][7].
- Other names
- AZD1656 + pioglitazone
02
Targets
GCK (Glucokinase)PPARG (Peroxisome proliferator-activated receptor gamma)
Beyond the preview
Go deeper on AZD1656 + pioglitazone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AZD1656 + pioglitazone.